Given that bone marrow-derived macrophages (BDMs) are recruited to the tumor by chemokine (C–C motif) ligand 2/CCL receptor 2 (CCL2/CCLR2) or colony-stimulating factor-1 (CSF-1)/CSF-1R axis, inhibitors targeting these ligands and receptors have been developed [140]. The gene discussed is CSF1R; the disease is neoplasm.